Shares of Provention Bio soared Monday after the biopharmaceutical company agreed to be acquired by France’s Sanofi (SNY) for $25 a share, or about $2.9 billion. Provention Bio (ticker: PRVB), which f...
Tag: Biotech and Pharma
Novavax Says ‘Substantial Doubt’ Around Its Continuing Operations
Covid-19 vaccine manufacturer Novavax said Tuesday that there is “substantial doubt” about its ability to continue operating through this year. In a quarterly earnings report issued after the market c...
For Nvidia Stock, It’s Game On!
These reports, excerpted and edited by Barron’s, were issued recently by investment and research firms. The reports are a sampling of analysts’ thinking; they should not be considered the views or rec...
Crispr Therapeutics: FDA Filing on Sickle Cell Gene Therapy Is Almost Done
An approval filing for a breakthrough treatment of sickle cell disease should be done by March, Crispr Therapeutics said, highlighting the company’s lead in a competitive area of medical research and ...
Pfizer CEO: Covid Infections Will Rise. So Will Paxlovid and Vaccine Sales.
Pfizer executives say Wall Street analysts haven’t understood just how powerful a hit the company’s Covid-19 products will take this year. That’s the explanation the company’s chief financial officer,...
Blackstone Stock Is a Good Investment, Even in a Downbeat Economy
These reports, excerpted and edited by Barron’s, were issued recently by investment and research firms. The reports are a sampling of analysts’ thinking; they should not be considered the views or rec...
CureVac Stock Just Got Upgraded. It’s Now a Competitor in mRNA Vaccines.
CureVac is ready to compete in the big leagues with its vaccines, according to a UBS analyst who says the soaring stock has more room to rise. UBS analyst Eliana Merle upgraded the shares (ticker: CVA...
Tanking Biotech Stocks Will Mean a Big Year for Deals. Who Could Benefit.
Nearly two years after biotechnology stocks began to tumble, executives at small and midsize companies in the space are finally accepting that share prices aren’t bouncing back anytime soon. With real...
It’s Pharma Time: Why Merck and Lilly Stock Are Buys, but not Pfizer.
My 2023 biotech outlook calls for continued momentum in name changes. I just need to figure out what the stocks will do. Last year, Respira Technologies became Qnovia. It’s run by a former tobacco exe...
Horizon Therapeutics, Coupa Software, Rivian, and More Stock Market Movers
This copy is for your personal, non-commercial use only. To order presentation-ready copies for distribution to your colleagues, clients or customers visit http://www.djreprints.com. https://www.barro...
CVS Wants to Be a Healthcare Provider. So Why Doesn’t It Have Any Doctors?
Late last year, CVS Health CEO Karen Lynch unveiled a new strategy: Rather than remain simply a pit stop for toilet paper and flu shots, CVS stores would become a place that Americans—particularly old...
Big Pharma Stocks Are Breaking Out. Here Are Some Winners.
Big pharma stocks are trying to break out to new heights. They have reported more-than-satisfactory earnings and are expecting further progress on new pipelines of drugs. These stocks had been outpe...
Pfizer Stock’s Post-Covid Future Looks Healthy
These reports, excerpted and edited by Barron’s, were issued recently by investment and research firms. The reports are a sampling of analysts’ thinking; they should not be considered the views or rec...
AbbVie Stock Slips as Sales Miss Expectations And Bigger Challenges Await.
Stock in AbbVie slipped after the drug company reported a higher profit than expected, while sales fell short. The revenue shortfall may have reminded investors of a challenge AbbVie (ticker: ABBV) fa...